Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H. Spelman T, et al. Among authors: pellegrini f. Neurol Clin Pract. 2016 Apr;6(2):102-115. doi: 10.1212/CPJ.0000000000000227. Neurol Clin Pract. 2016. PMID: 27104064 Free PMC article.
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; TYSABRI Observational Program (TOP) Investigators. Butzkueven H, et al. Among authors: pellegrini f. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1190-7. doi: 10.1136/jnnp-2013-306936. Epub 2014 Feb 14. J Neurol Neurosurg Psychiatry. 2014. PMID: 24532785 Free PMC article. Clinical Trial.
Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, Grand-Maison F, Izquierdo G, Grammond P, Duquette P, Lugaresi A, Lechner-Scott J, Oreja-Guevara C, Hupperts R, Petersen T, Barnett M, Trojano M, Butzkueven H. Spelman T, et al. Among authors: pellegrini f. Ann Clin Transl Neurol. 2015 Apr;2(4):373-87. doi: 10.1002/acn3.180. Epub 2015 Feb 27. Ann Clin Transl Neurol. 2015. PMID: 25909083 Free PMC article.
Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
Wiendl H, Butzkueven H, Kappos L, Trojano M, Pellegrini F, Paes D, Zhang A, Belachew S; Tysabri® Observational Program (TOP) Investigators. Wiendl H, et al. Among authors: pellegrini f. PLoS One. 2016 Jan 15;11(1):e0144834. doi: 10.1371/journal.pone.0144834. eCollection 2016. PLoS One. 2016. PMID: 26771747 Free PMC article. Clinical Trial.
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Trojano M, et al. Among authors: pellegrini f. Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. Mult Scler Relat Disord. 2018. PMID: 29860197 Free article.
449 results